U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping more than 50 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.13% to 33,446.10 while the NASDAQ fell 0.55% to 12,059.75. The S&P 500, also fell, dropping, 0.20% to 4,092.45.
InflaRx NV’s (NASDAQ:IFRX) stock is up Wednesday morning as the FDA granted emergency-use authorization to its monoclonal antibody for hospitalized COVID…
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune response
FDA granted EUA based on Phase III clinical trial
Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients
EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The
InflaRx (NASDAQ:IFRX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
InflaRx reported EPS of $0.01.
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings (CCNB).
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.